Exciting news is making waves in the fight against HIV. A promising new drug, lenacapavir, is on the verge of being approved in the U.S., offering hope to millions worldwide. This innovative, long-acting injection could prevent HIV infection with just two doses a year — a significant breakthrough in prevention technology.

Even better, research indicates that the drug could be produced and sold for as little as $25 a year, making it incredibly affordable compared to current options that can cost thousands annually. Experts believe that at this price point, the drug could reach people in need across the globe, especially in low-income countries hardest hit by the epidemic.

Gilead, the manufacturer, is working with generic companies to ensure manufacturing in 120 low-income countries, and plans to provide doses at no profit initially. Advocates emphasize that affordable access to such breakthrough medicines could dramatically reduce new infections and save countless lives.

This story reminds us that innovation combined with compassion can create real change. As the world moves closer to ending HIV, the hope is that everyone—regardless of where they live—can benefit from these advances. It’s a shining example of what’s possible when science and social good unite.